Skip to main content
The Egyptian Heart Journal

Table1 Reduction in heart failure hospitalisation and CV death with empagliflozin, dapagliflozin,canagliflozin and ertugliflozin

From: SGLT2 inhibitors in heart failure with reduced ejection fraction

 

EMPA-REG OUTCOME (empagliflozin)

VERTIS CV (ertugliflozin)

CANVAS program (canagliflozin)

DECLARE TIMI (dapagliflozin)

 

(RRR)

(RRR)

(RRR)

(RRR)

HHF

35% ↓

30% ↓

33% ↓

27% ↓

CV death

38% ↓

8% ↓

13% ↓

2% ↓

  1. HHF hospitalisation for heart failure, CV death Cardiovascular death, RRR Relative risk reduction
Back to article page